Variability in intestinal drug metabolizing enzymes and transporters in Crohn's disease and potential impact on oral drug absorption
CD inflammation significantly suppresses the expression of intestinal DMETs, which, together with changes in other system parameters, can alter the fate of drugs taken orally in these patients. Virtual patients within a PBPK framework, informed by the measured DMET ranges in the intestine, may serve as a guide for dose adjustment in the absence of dedicated clinical studies.
Authors
- Jill Barber (ORCID: https://orcid.org/0000-0002-5424-0291)
- Zubida M. Al‐Majdoub
- Amin Rostami‐Hodjegan (ORCID: https://orcid.org/0000-0003-3917-844X)
- Sarah Alrubia (ORCID: https://orcid.org/0000-0003-1892-2452)
- Brahim Achour (ORCID: https://orcid.org/0000-0002-2595-5626)
Institutions
- University of Rhode Island (US)
- King Saud University (SA)
- University of Manchester (GB)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-03-04
- DOI
- https://doi.org/10.1002/bcp.70019
- Citations
- 2
- Primary Topic
- Drug Transport and Resistance Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 2.09